Issues on Safety of Long-Acting Muscarinic Antagonist / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 384-389, 2011.
Artículo
en Coreano
| WPRIM
| ID: wpr-181457
ABSTRACT
The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result. Long-acting inhaled muscarinic antagonists (LAMAs) is a preferred treatment modality. However, the cardiovascular (CV) safety of anti-cholinergics, including LAMA, has been an issue. In contrast, the results of the UPLIFT trial and a pooled analysis of data from 30 trials of tiotropium illustrates the association of tiotropium with reductions in the risk of all cause mortality, CV mortality and CV events. And, the UPLIFT trial provides clues regarding the additive advantages of tiotropium in COPD patients who already are using long-acting inhaled beta2 agonists and inhaled corticosteroids. Following the contribution of tiotropium as a first LAMA, new LAMAs such as aclidinium and glycopyrrolate (NVA-237) seem to be emerging.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Derivados de Escopolamina
/
Comorbilidad
/
Corticoesteroides
/
Antagonistas Muscarínicos
/
Antagonistas Colinérgicos
/
Polifarmacia
/
Enfermedad Pulmonar Obstructiva Crónica
/
Bromuro de Tiotropio
/
Glicopirrolato
Límite:
Humanos
Idioma:
Coreano
Revista:
Tuberculosis and Respiratory Diseases
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS